ArticleBMC infectious diseases2025
Risk factors analysis for progression to severe hepatitis in acute hepatitis E: a retrospective study of 146 hospitalized cases.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis E virus (HEV) infection typically presents as a self-limiting acute hepatitis, but a subset of patients may progress to severe hepatitis, with potential progression to liver failure or even death. Identifying clinical predictors of such severe progression is essential for early risk stratification and timely intervention. This study aimed to investigate independent risk factors associated with severe outcomes in acute HEV infection.
methodsA retrospective analysis was conducted on 146 hospitalized patients diagnosed with acute HEV infection at Shanghai Ninth People's Hospital from January 2017 to May 2025. Demographic data, laboratory parameters, and clinical outcomes were systematically collected. Correlation analysis and logistic regression models were applied to identify independent risk factors for disease severity.
results45 patients (30.8%) progressed to severe hepatitis. Increasing age, elevated white blood count(WBC), decreased hemoglobin(HGB) and reduced CD4+ T cell counts were associated with higher risk of severe outcomes. Multivariate logistic regression identified elevated WBC count (OR=1.226, 95% CI:1.006–1.495, p=0.044) and decreased HGB level (OR=0.948, 95% CI:0.915–0.983, p=0.004) as independent risk factors. Further, WBC ≥9×109/L and HGB <90 g/L were significantly associated with severe outcomes. The protective effect of elevated HGB was more pronounced in male patients (P_interaction = 0.003) and those with underlying liver disease (P_interaction = 0.026)
conclusionElevated WBC count and reduced HGB level are critical indicators for predicting severe hepatitis outcomes in patients with acute HEV infection. Monitoring these specific blood indicators can assist clinicians in identifying high–risk patients and taking preemptive measures to halt disease progression. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.